PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2142 Views
-
Last post by NHE
-
- 0 Replies
- 1018 Views
-
Last post by NHE
-
- 0 Replies
- 10275 Views
-
Last post by NHE
-
- 0 Replies
- 2054 Views
-
Last post by Firidion
-
- 1 Replies
- 1354 Views
-
Last post by vesta
-
- 0 Replies
- 2054 Views
-
Last post by frodo
-
- 0 Replies
- 1973 Views
-
Last post by NHE
-
- 0 Replies
- 1509 Views
-
Last post by NHE
-
- 4 Replies
- 2483 Views
-
Last post by JohnC777